Interstitial Lung Disease Medical Slides
Generate publication-quality interstitial lung disease lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Interstitial Lung Disease DeckWhy teach Interstitial Lung Disease?
Interstitial lung diseases encompass over 200 distinct entities with a combined prevalence of approximately 80 per 100,000. The 2022 ATS/ERS/JRS/ALAT guidelines emphasize multidisciplinary discussion (MDD) as the diagnostic gold standard, integrating clinical, radiological, and pathological data. Teaching ILD requires systematic HRCT pattern recognition and understanding of the diagnostic framework that guides management decisions.
What AI generates for Interstitial Lung Disease
Enter “Interstitial Lung Disease” and SlideCraft generates a complete lecture deck with slides like these.
See it in action
Type any medical topic and watch AI generate a presentation slide in seconds. No signup required.
3 free previews per hour · No account needed
Enter a topic and click Generate to see your AI slide
Interstitial Lung Disease Presentation FAQ
How should HRCT pattern recognition be taught in ILD slides?
Present the four key patterns with characteristic features: UIP (basal-predominant honeycombing, traction bronchiectasis, minimal ground-glass), NSIP (basal ground-glass with subpleural sparing), OP (consolidation in peribronchial distribution, reversed halo sign), and HP (upper/mid-zone mosaic attenuation with air trapping). Emphasize that a definite UIP pattern on HRCT has >90% positive predictive value for histological UIP, often avoiding surgical biopsy.
What serological workup should be highlighted for ILD evaluation?
Present the systematic screening panel: ANA (CTD screen), RF and anti-CCP (rheumatoid arthritis), anti-Scl-70 and anti-centromere (scleroderma), anti-Jo-1 and other myositis-specific antibodies (antisynthetase syndrome), ANCA (vasculitis). Include serum KL-6 and SP-D as ILD activity biomarkers. Emphasize that up to 15% of apparently idiopathic ILD is reclassified as CTD-ILD after comprehensive autoimmune evaluation.
How should antifibrotic therapy evidence be presented?
Reference the pivotal trials: pirfenidone (ASCEND, 2014) reduced FVC decline by 50% in IPF; nintedanib (INPULSIS, 2014) reduced FVC decline by 50% in IPF. Present the expanding indications — nintedanib for progressive fibrosing ILD (INBUILD trial, 2019) and SSc-ILD (SENSCIS trial). Discuss the 2022 guidelines recommending antifibrotics for progressive pulmonary fibrosis regardless of underlying ILD diagnosis.
Simple pricing, no surprises
Start free today. Upgrade when your department needs more.
Free
Try SlideCraft with no commitment
- 2 decks per month
- AI slides with speaker notes
- View & present only (no export)
- 7-day cloud storage
- Slide Checker & Outline Generator
Pro
For clinicians who lecture weekly
- 10 decks/mo + $2.50/extra
- AI Critic Mode (5-axis review)
- Document-to-deck (PDF upload)
- PDF, PPTX, SCORM & image export
- Permanent cloud storage
Expert
For academic physicians who publish and present
- 25 decks/mo + $2.00/extra
- PubMed source verification
- Paper-to-deck pipeline
- Auto-citations (Vancouver)
- Everything in Pro